118 related articles for article (PubMed ID: 36669615)
1. Silibinin chronic treatment in a rat model of Parkinson disease: A comprehensive in-vivo evaluation and in silico molecular modeling.
Eyvari Brooshghalan S; Sabahi M; Ebadi SA; Sadeghian Z; Mohajjel Nayebi A; Haddadi R
Eur J Pharmacol; 2023 Feb; 941():175517. PubMed ID: 36669615
[TBL] [Abstract][Full Text] [Related]
2. Pre-treatment with silymarin reduces brain myeloperoxidase activity and inflammatory cytokines in 6-OHDA hemi-parkinsonian rats.
Haddadi R; Mohajjel Nayebi A; Brooshghalan SE
Neurosci Lett; 2013 Oct; 555():106-11. PubMed ID: 24045063
[TBL] [Abstract][Full Text] [Related]
3. Silymarin prevents apoptosis through inhibiting the Bax/caspase-3 expression and suppresses toll like receptor-4 pathway in the SNc of 6-OHDA intoxicated rats.
Haddadi R; Nayebi AM; Eyvari Brooshghalan S
Biomed Pharmacother; 2018 Aug; 104():127-136. PubMed ID: 29772432
[TBL] [Abstract][Full Text] [Related]
4. Gastrodin microinjection suppresses 6-OHDA-induced motor impairments in parkinsonian rats: insights into oxidative balance and microglial activation in SNc.
Haddadi R; Poursina M; Zeraati F; Nadi F
Inflammopharmacology; 2018 Oct; 26(5):1305-1316. PubMed ID: 29616453
[TBL] [Abstract][Full Text] [Related]
5. Effect of Chronic Administration of Buspirone and Fluoxetine on Inflammatory Cytokines in 6-Hydroxydopamine-lesioned Rats.
Sharifi H; Nayebi AM; Farajnia S; Haddadi R
Drug Res (Stuttg); 2015 Aug; 65(8):393-7. PubMed ID: 24782287
[TBL] [Abstract][Full Text] [Related]
6. Post treatment with Gastrodin suppresses oxidative stress and attenuates motor disorders following 6-OHDA induced Parkinson disease.
Sadeghian Z; Eyvari-Brooshghalan S; Sabahi M; Nourouzi N; Haddadi R
Neurosci Lett; 2022 Nov; 790():136884. PubMed ID: 36162540
[TBL] [Abstract][Full Text] [Related]
7. Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT
Pinna A; Costa G; Serra M; Contu L; Morelli M
Neuropharmacology; 2021 Sep; 196():108693. PubMed ID: 34229013
[TBL] [Abstract][Full Text] [Related]
8. Changes in cytokines and neurotrophins in Parkinson's disease.
Nagatsu T; Mogi M; Ichinose H; Togari A
J Neural Transm Suppl; 2000; (60):277-90. PubMed ID: 11205147
[TBL] [Abstract][Full Text] [Related]
9. Betanin improves motor function and alleviates experimental Parkinsonism via downregulation of TLR4/MyD88/NF-κB pathway: Molecular docking and biological investigations.
ElSayed MH; Atif HM; Eladl MA; Elaidy SM; Helaly AMN; Hisham FA; Farag NE; Osman NMS; Ibrahiem AT; Khella HWZ; Bilasy SE; Albalawi MA; Helal MA; Alzlaiq WA; Zaitone SA
Biomed Pharmacother; 2023 Aug; 164():114917. PubMed ID: 37244180
[TBL] [Abstract][Full Text] [Related]
10. Alterations in the cellular distribution of bcl-2, bcl-x and bax in the adult rat substantia nigra following striatal 6-hydroxydopamine lesions.
Kramer BC; Mytilineou C
J Neurocytol; 2004 Mar; 33(2):213-23. PubMed ID: 15322379
[TBL] [Abstract][Full Text] [Related]
11. Oral Administration of Silibinin Ameliorates Cognitive Deficits of Parkinson's Disease Mouse Model by Restoring Mitochondrial Disorders in Hippocampus.
Liu X; Wang C; Liu W; Song S; Fu J; Hayashi T; Mizuno K; Hattori S; Fujisaki H; Ikejima T
Neurochem Res; 2021 Sep; 46(9):2317-2332. PubMed ID: 34097239
[TBL] [Abstract][Full Text] [Related]
12. Effects of WR1065 on 6-hydroxydopamine-induced motor imbalance: Possible involvement of oxidative stress and inflammatory cytokines.
Kheradmand A; Nayebi AM; Jorjani M; Khalifeh S; Haddadi R
Neurosci Lett; 2016 Aug; 627():7-12. PubMed ID: 27222379
[TBL] [Abstract][Full Text] [Related]
13. Silibinin, a natural flavonoid, modulates the early expression of chemoprevention biomarkers in a preclinical model of colon carcinogenesis.
Kauntz H; Bousserouel S; Gosse F; Marescaux J; Raul F
Int J Oncol; 2012 Sep; 41(3):849-54. PubMed ID: 22735354
[TBL] [Abstract][Full Text] [Related]
14. 8-OH-DPAT (5-HT1A agonist) Attenuates 6-Hydroxy- dopamine-induced catalepsy and Modulates Inflammatory Cytokines in Rats.
Sharifi H; Mohajjel Nayebi A; Farajnia S
Iran J Basic Med Sci; 2013 Dec; 16(12):1270-5. PubMed ID: 24570834
[TBL] [Abstract][Full Text] [Related]
15. Effect of WR-1065 on 6-hydroxydopamine-induced catalepsy and IL-6 level in rats.
Kheradmand A; Nayebi AM; Jorjani M; Haddadi R
Iran J Basic Med Sci; 2016 May; 19(5):490-6. PubMed ID: 27403255
[TBL] [Abstract][Full Text] [Related]
16. Dopaminergic neuronal death in the substantia nigra associates with change in serum levels of TNF-α and IL-1β; evidence from early experimental model of Parkinson's disease.
Piri H; Sharifi S; Nigjeh S; Haghdoost-Yazdi H
Neurol Res; 2022 Jun; 44(6):544-553. PubMed ID: 34986749
[TBL] [Abstract][Full Text] [Related]
17. Perillyl Alcohol Mitigates Behavioural Changes and Limits Cell Death and Mitochondrial Changes in Unilateral 6-OHDA Lesion Model of Parkinson's Disease Through Alleviation of Oxidative Stress.
Anis E; Zafeer MF; Firdaus F; Islam SN; Khan AA; Hossain MM
Neurotox Res; 2020 Aug; 38(2):461-477. PubMed ID: 32394056
[TBL] [Abstract][Full Text] [Related]
18. Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats.
Mahmoudi J; Nayebi AM; Samini M; Reyhani-Rad S; Babapour V
Pharmacol Rep; 2011; 63(4):908-14. PubMed ID: 22001978
[TBL] [Abstract][Full Text] [Related]
19. Hydrogen sulphide attenuates neuronal apoptosis of substantia nigra by re-establishing autophagic flux via promoting leptin signalling in a 6-hydroxydopamine rat model of Parkinson's disease.
Jiang W; Zou W; Hu M; Tian Q; Xiao F; Li M; Zhang P; Chen YJ; Jiang JM
Clin Exp Pharmacol Physiol; 2022 Jan; 49(1):122-133. PubMed ID: 34494284
[TBL] [Abstract][Full Text] [Related]
20. Silibinin attenuates MPP⁺-induced neurotoxicity in the substantia nigra in vivo.
Jung UJ; Jeon MT; Choi MS; Kim SR
J Med Food; 2014 May; 17(5):599-605. PubMed ID: 24660866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
